Tumor heterogeneity is a major problem for developing improved cancer treatments. Although individual therapies may often treat portions of a tumor, differential response of subclones is an important reason for cancer recurrence. So far, precisely identifying subclones and their rates of evolution has been challenging. This is because of the lack of fine longitudinal data from patient tumors, as matched recurrences or metastases are often temporally distant from the original tumor. Patient-derived xenografts (PDXs), i.e. human tumors engrafted and further studied in mice, are a model in which tumors can be dissected and then propagated for controllable time intervals, making them a potentially powerful system for studying changes in tumor subclonal populations. In preliminary studies we have used high-depth sequencing to sensitively detect somatic mutations in PDX fragments. Moreover, we have shown that these mutations change in prevalence as a xenograft grows. In this exploratory study, we propose to test and apply PDXs as an improved system to quantify rates of tumor subclonal population evolution. We will pursue this in two specific aims.
In Aim 1, we will spatially dissect PDX triple negative breast cancer tumors derived from two separate patients, selectively sequence and propagate interlaced fragments from the tumors, and then sequence the propagated fragments after allowing them to evolve in vivo over several months. These experiments will provide rich, cross-validating data that we will analyze with new computational approaches to significantly improve not only identification of subclones within tumors, but also the rates at which subclones mutate and change in prevalence in bulk tumors. To confirm these approaches, we will perform single cell sequencing of hundreds of cells from these tumors.
In Aim 2, we will perform parallel studies on xenografts grown from the same two patient tumors as in Aim 1 but treated with standard-of-care drug therapy. This will allow us to compare how these subclonal populations evolve in conditions similar to a treated patient tumor. If successful, this study will yield a validated, generalizable approach for studying tumor evolution that could be applied to a wide variety of cancers.

Public Health Relevance

Over one million Americans are diagnosed with cancer annually, and cancer recurrence is a main cause of death. Recurrence is due to the re-emergence of tumor cells that were not eradicated during initial treatment. In this proposal, we will explore why certain populations of tumor cells persist and become more prominent after treatment. We will evaluate these issues in mice implanted with cancer cells derived from human cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
3R21CA191848-01A1S1
Application #
9156904
Study Section
Program Officer
Li, Jerry
Project Start
2016-02-03
Project End
2016-06-30
Budget Start
2016-02-03
Budget End
2016-06-30
Support Year
1
Fiscal Year
2016
Total Cost
$75,600
Indirect Cost
$35,600
Name
Jackson Laboratory
Department
Type
DUNS #
042140483
City
Bar Harbor
State
ME
Country
United States
Zip Code
04609
Kim, Hyunsoo; Kumar, Pooja; Menghi, Francesca et al. (2018) High-resolution deconstruction of evolution induced by chemotherapy treatments in breast cancer xenografts. Sci Rep 8:17937
Noorbakhsh, Javad; Kim, Hyunsoo; Namburi, Sandeep et al. (2018) Distribution-based measures of tumor heterogeneity are sensitive to mutation calling and lack strong clinical predictive power. Sci Rep 8:11445
Bais, Preeti; Namburi, Sandeep; Gatti, Daniel M et al. (2017) CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens. Bioinformatics 33:3110-3112
Noorbakhsh, Javad; Chuang, Jeffrey H (2017) Uncertainties in tumor allele frequencies limit power to infer evolutionary pressures. Nat Genet 49:1288-1289
Menghi, Francesca; Inaki, Koichiro; Woo, XingYi et al. (2016) The tandem duplicator phenotype as a distinct genomic configuration in cancer. Proc Natl Acad Sci U S A 113:E2373-82
Rajbhandari, Rajani; McFarland, Braden C; Patel, Ashish et al. (2015) Loss of tumor suppressive microRNA-31 enhances TRADD/NF-?B signaling in glioblastoma. Oncotarget 6:17805-16